<DOC>
	<DOCNO>NCT00087425</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , bryostatin 1 , work different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Bryostatin 1 may help rituximab kill cancer cell make sensitive drug . PURPOSE : This phase II trial study well give bryostatin 1 together rituximab work treat patient B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia respond previous treatment rituximab .</brief_summary>
	<brief_title>Bryostatin 1 Rituximab Treating Patients With B-Cell Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility safety bryostatin 1 rituximab patient rituximab-refractory indolent B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia ( CLL ) . - Determine antitumor response patient treat regimen . Secondary - Determine effect regimen functional molecular status effector cell ( i.e. , NK cell , monocyte , dendritic cell ) patient . - Determine expression CD20 complement-inhibitory molecule tumor cell treatment regimen patient . - Determine effect regimen global gene expression pattern CLL cell patient . OUTLINE : This multicenter study . Patients receive bryostatin 1 IV continuously 24 hour day -6 , 2 , 9 course 1 day 2 9 course 2-6 . Patients also receive rituximab IV 4 hour day 1 , 8 , 15 , 22 course 1 4 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 18-48 patient ( 9-24 non-Hodgkin 's lymphoma 9-24 chronic lymphocytic leukemia ) accrue study within 12-30 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically cytologically confirm disease : Indolent Bcell nonHodgkin 's lymphoma ( NHL ) Stage IIIV disease Chronic lymphocytic leukemia ( CLL ) meet 1 follow risk criterion : Intermediaterisk progressive disease Highrisk , modify Rai stage disease CD20positive flow cytometry immunohistochemistry Measurable disease Rituximabrefractory disease , defined failure achieve response last course prior treatment rituximab alone combination therapeutic modality No know neoplastic leptomeningeal involvement and/or brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 50,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 2.5 time upper limit normal Bilirubin normal ( unless due Gilbert 's disease organ involvement NHL CLL ) Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No history anaphylaxis immunoglobulin ( Ig ) Emediated hypersensitivity murine protein Prior infusion reaction rituximab without IgE component allow No active ongoing infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics See Radiotherapy At least 12 week since prior rituximab More 4 week since prior immunotherapy recover Chemotherapy No 3 prior chemotherapy regimens More 4 week since prior chemotherapy recover Endocrine therapy No concurrent glucocorticoid Radiotherapy At least 12 week since prior radioimmunotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other At least 4 week since prior therapy malignancy No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>